According to the University of Michigan National Poll on Healthy Aging (2023), 80% of adults aged 65 to 80 did not receive a cognitive assessment in the prior year.
That gap has real consequences for Medicare Advantage plans and health systems managing aging populations. Undetected cognitive impairment compounds the cost of every chronic condition it touches and leaves risk adjustment documentation incomplete.
Neurotrack gives health plans and providers a digital cognitive screener that fits inside existing AWV workflows, generating structured clinical documentation in as little as three minutes.
This article explains what digital cognitive screening looks like inside a Medicare Annual Wellness Visit (AWV), why CMS requires cognitive impairment detection, and how health plan care management leaders can use it to improve compliance, documentation, and early intervention.
Digital cognitive screening uses validated, software-based tasks to measure cognitive domains such as memory, attention, and processing speed. Unlike paper-based tools that rely on clinician administration and subjective scoring, digital screeners deliver standardized instructions and automatically generate scored results.
These tools can be self-administered by patients on a tablet or other device, either in the clinic or remotely. The scored output feeds directly into electronic health records, creating structured clinical documentation without additional data entry from staff.
For Medicare Advantage payers and care management teams, digital screening offers a way to move cognitive impairment detection from an ad hoc clinical impression to a consistent, repeatable, and scalable process across member populations.
Since 2011, CMS has required that every Medicare Annual Wellness Visit include detection of any cognitive impairment the patient may have. The requirement applies to both the initial AWV and every subsequent visit.
CMS defines this as assessment of cognitive function through direct observation, patient or caregiver report, and consideration of brief cognitive tests when appropriate.
CMS does not mandate a specific screening instrument. Clinicians may choose any validated method that supports their clinical judgment and meets documentation standards. This flexibility creates an opening for digital tools that can standardize the process while saving time.
The Alzheimer's Association 2025 Facts and Figures report estimates that 61% of dementia cases remain undiagnosed. The number of Americans living with Alzheimer's disease has surpassed 7 million for the first time. Routine screening during AWVs creates a systematic path to catch cognitive decline before it progresses.
A digital cognitive screener is typically administered at the start of the AWV or as a pre-visit activity. The patient completes a series of short tasks on a tablet or device. These tasks measure performance across cognitive domains aligned with DSM-5 criteria for neurocognitive disorders.
Results are scored automatically and delivered to the provider before or during the encounter. The clinician reviews the report, considers it alongside the patient's history and observations, and determines whether further evaluation or a referral is warranted.
Neurotrack's digital cognitive screener completes the first assessment step in three minutes. Smart Logic, the platform's adaptive intelligence layer, dynamically adjusts the assessment based on how a patient responds.
This produces a more accurate clinical picture without extending the encounter. Results integrate directly into the EHR, generating documentation that supports both clinical decision-making and compliant coding.
Paper-based tools like the Mini-Cog, SLUMS, and MoCA have served primary care for years, but they come with well-documented operational limitations. Administration typically takes 10 to 30 minutes, requires trained staff, and produces results that vary depending on who administers and scores the test.
Digital screeners address each of these friction points. They standardize the testing environment, deliver uniform scoring, and reduce the time burden on clinical staff.
According to a 2025 Practical Neurology review, digital assessments may also improve measurement accuracy for reaction time and motor functioning while enabling more frequent longitudinal monitoring.
For health plan care management teams overseeing large populations, the operational difference is significant. A three-minute, patient-led screener that feeds structured data into the EHR can be deployed at scale across primary care networks, health systems, and in-home evaluation programs without requiring additional clinical headcount.
CMS's HCC V28 risk adjustment model, now fully implemented for payment year 2026, codes dementia across three severity tiers: mild, moderate, and severe. Every level of diagnostic specificity in a member's cognitive record has a direct impact on risk-adjusted revenue for Medicare Advantage plans.
When cognitive impairment goes unscreened and undocumented, health plans absorb the elevated costs of a high-acuity population without capturing the corresponding risk adjustment. Neurotrack's platform generates the clinical documentation that supports accurate cognitive coding, helping health plans close the gap between actual member complexity and documented acuity.
This is especially relevant for PACE programs and special needs plans, where members carry disproportionately high rates of cognitive impairment. Systematic digital screening across these populations creates a documented clinical baseline that coding and compliance teams can work from.
Identifying cognitive impairment at the mild stage opens clinical options that are unavailable once the disease progresses. Anti-amyloid therapies are approved only for patients diagnosed with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Without early screening, many of these patients are identified too late to be eligible for treatment.
Digital screening also activates downstream care pathways. A positive screen can trigger a structured clinical workflow that includes diagnostic confirmation, care planning, caregiver support, and referral to specialists or community resources.
Neurotrack connects detection to direction through patient-specific care plans powered by Smart Logic, giving providers a clear path from a screening result to a clinical action.
For care management leaders, this means shifting from reactive crisis management to proactive population health strategy. According to the Alzheimer's Association 2025 report, nearly 4 in 5 Americans surveyed said they would want to know if they had Alzheimer's before symptoms interfered with daily activities.
The demand for early detection is there. Digital screening makes it operationally achievable.
Implementing digital cognitive screening across a Medicare Advantage population requires alignment between clinical operations, provider networks, and compliance teams. The process starts with selecting a validated screener that fits inside existing AWV workflows without adding time or staff burden.
Neurotrack's platform is device-agnostic and can be administered in clinic, remotely, or in the home. It integrates directly into EHR environments, including Epic, and requires minimal training for clinical staff. Deployment typically takes weeks, not months, making it operationally feasible for health plans managing large provider networks.
Health plans should also consider how screening data connects to downstream workflows. Structured screening output should feed into care management platforms, trigger referral pathways, and support compliant documentation for RADV audits.
The goal is a closed-loop system where screening generates both clinical insight and operational data that health plans can act on across their member populations.
When evaluating digital cognitive screening platforms, care management leaders should prioritize clinical validation, workflow integration, and scalability. The tool should be validated for detecting cognitive impairment at the mild stage, not just distinguishing dementia from normal cognition.
EHR integration matters. A platform that generates EMR-ready documentation eliminates manual data entry, reduces errors, and ensures screening results are immediately available to the care team. Look for tools that produce structured output aligned with CMS documentation requirements and HCC coding standards.
Accessibility and equity should factor into the decision. Assessments that use culturally agnostic design elements, like symbols and numbers instead of language-dependent tasks, reduce bias across diverse member populations. Neurotrack's assessments are designed to minimize cultural and educational bias, supporting equitable screening across the populations that Medicare Advantage plans serve.
Digital cognitive screening transforms the AWV cognitive impairment detection requirement from a compliance checkbox into a clinical and financial advantage. For Medicare Advantage payers and care management leaders, it provides a scalable path to identify cognitive decline earlier, document it accurately, and activate care pathways that improve outcomes and reduce downstream costs.
Neurotrack's cognitive care enablement platform brings clinically validated screening, adaptive assessment logic, and structured care planning together in a single, workflow-embedded solution. If you are ready to close the cognitive care gap across your member population, now is the time to act.
Yes. CMS requires detection of cognitive impairment at both the initial and subsequent AWVs. Clinicians must assess cognitive function through observation, patient or caregiver report, or a brief cognitive test. CMS does not mandate a specific tool.
Most digital screeners complete in under 10 minutes. Neurotrack's digital cognitive screener completes the first assessment step in three minutes, saving an average of ten minutes per encounter compared to paper-based tools. This makes routine screening operationally feasible during a standard AWV.
Digital screening generates structured clinical documentation that supports accurate cognitive coding under CMS's HCC V28 model. Neurotrack produces EHR-ready output that helps health plans capture the diagnostic specificity required for risk-adjusted revenue across mild, moderate, and severe dementia tiers.
Yes. Neurotrack's platform is device-agnostic and supports in-clinic, remote, and in-home administration. This flexibility is especially valuable for health plans using in-home evaluation models to reach members who may not attend in-office AWVs regularly.
Neurotrack delivers clinically validated assessments sensitive enough to detect cognitive impairment at the mild cognitive impairment stage. Smart Logic adapts each assessment in real time based on patient responses, and the platform connects screening results to structured care pathways and patient-specific care plans, giving providers a clear path from detection to action.